This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign In or Register
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

ZAVICEFTA® (ceftazidime - avibactam): For the management of serious infections in critically ill patients

ZAVICEFTA (ceftazidime and avibactam), for the treatment of patients at high risk of MDR Gram-negative infections with suspected or documented P. aeruginosa, CRE (KPC, OXA-48), and ESBL- and AmpC-producing pathogens1-4.

Mode of action video

ZAVICEFTA is indicated for the treatment of adult and paediatric patients aged 3 months and older with the following infections:1*

Complicated intra-abdominal infection (cIAI)
Complicated urinary tract infection (cUTI), including pyelonephritis
Hospital‑acquired pneumonia (HAP), including ventilator‑associated pneumonia (VAP)
Treatment of adult patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. ZAVICEFTA is also indicated for the treatment of infections due to aerobic Gram‑negative organisms in adult patients with limited treatment options.
*Consideration should be given to the official guidance on the appropriate use of antibacterial agents.1
†Data support the use of ZAVICEFTA in patients with Limited Treatment Options for the treatment of bacteraemia, cSSTI, BSI, meningitis due to KPC and OXA‑48 resistance mechanisms, and MDR Pseudomonas.7-12

Access results of ZAVICEFTA Phase III clinical trials in adult patients with cUTI, cIAI or HAP/VAP

View Phase III trial results

Learn more about the safety data of ZAVICEFTA from 4 Phase III clinical trials

View safety profile

Learn about ZAVICEFTA dosing across patient populations, preparation & administration, and shelf life & storage

Access dosing guide

Explore more​​​​​​​

Patient Risk Factors

Identifying patients at risk of MDR Gram-negative infections is vital for appropriate selection of adequate, early antimicrobial therapy to reduce the risk of fatal outcomes5.

View patient risk factors

Pathogen coverage

ZAVICEFTA has broad spectrum coverage against Gram-negative pathogens including in vitro activity against MDR P.aeruginosa, CRE, including KPC- and OXA-48 producing strains, and ESBL- and AmpC-producing bacteria1-4.

Learn about coverage

Antimicrobial Stewardship

Access our resources for implementation of an Antimicrobial Stewardship Programme and learn more about Pfizer initiatives to fight AMR

Access resources


cUTI, complicated urinary tract infection; cIAI, complicated intra-abdominal infection; HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia; MDR, multi-drug resistant; BL/BLI, β-lactam/β-lactamase inhibitors; CRE, carbapenem-resistant Enterobacteriaceae; KPC, Klebsiella pneumoniae carbapenemase; MBL, metallo-β-lactamase; OXA, oxacillinase; ESBL, extended-spectrum β-lactamase, BSI, bloodstream infection; cSSTI, complicated skin and soft tissue.

  1. ​​​​​​​ZAVICEFTA. Summary of Product Characteristics
  2. Liscio JL, et al. Int J Antimicrob Agents 2015;46:266–7
  3. Nicolau DP, et al. J Antimicrob Chemother 2015;70:2862–9
  4. Mazuski JE, et al. Surg Infect 2017;18:1–76 
  5. Bonine NG, et al. Am J Med Sci 2019;357:102–10​​​​​​​
  6. Morris, AC. JECCM 2018;2:101-01.
  7. Tumbarello M, et al. Clin Infect Dis 2012;55:943–50
  8. Caston JJ, et al. J Infect Dis 2017;59:118–23
  9. Van Duin D, et al. J Clin Infect Dis 2018;66:163–71
  10. Sousa A, et al. Antimicrob Chemother 2018;73:3170–5
  11. Temkin E, et al. Antimicrob Agents Chemother 2017;61:e01964-16
  12. Shields K, et al. Antimicrob Agents Chemother 2017;61:e00883-17
PP-ZVA-GBR-1418. February 2022

Access case studies and videos

  • Management of MDR Gram-negative infections

  • ZAVICEFTA in clinical practice

  • Webinars

Ask Zavibot a Question
Efficacy of Zavicefta

Find out more about the safety and efficacy of Zavicefta 

Efficacy and Safety

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021



OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?